Acrivon Therapeutics, Inc. Stock Price, News & Analysis

Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Peter Blume-Jensen will participate in a fireside chat on May 2, 2023, at 3:00 p.m. ET during the H.C. Wainwright BioConnect Investor Conference in New York. The company focuses on developing precision oncology medicines using its proprietary proteomics-based platform, known as Acrivon Predictive Precision Proteomics (AP3). Acrivon’s leading candidate, ACR-368, targets CHK1 and CHK2 and is in a Phase 2 trial for various tumor types. The OncoSignature® companion diagnostics, although not yet regulatory approved, aim to identify patients likely to benefit from ACR-368. Acrivon also explores preclinical programs targeting other nodes in DNA Damage Response, including WEE1 and PKMYT1.

Acrivon Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ACRV), will host a virtual investor event on May 1, 2023, from 11:00 a.m. to 12:00 p.m. ET. The agenda includes a company overview, an update on the Acrivon Predictive Precision Proteomics (AP3) platform, details on the preclinical pipeline, clinical trial enrollment progress, and corporate updates.

The event can be accessed via the company’s investor website, and a replay will be available for 90 days. Acrivon focuses on precision oncology medicines, utilizing its AP3 platform for patient responder identification and developing the lead candidate ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial across various tumor types. The company is also exploring additional preclinical programs targeting critical nodes in DNA Damage Response.

Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that its CEO, Peter Blume-Jensen, will participate in a fireside chat at the Stifel 2023 Targeted Oncology Days Conference on April 25, 2023, at 3:00 p.m. ET. This event will be held virtually and will focus on Acrivon’s advancements in precision oncology medicines.

Acrivon’s proprietary platform, AP3, matches patients’ tumor sensitivities to specific drugs. The company is advancing its lead candidate, ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial. Acrivon also develops OncoSignature companion diagnostics to identify patients most likely to benefit from its drug candidates. A replay of the webcast will be available for 90 days after the event.

Acrivon Therapeutics (Nasdaq: ACRV) reported its financial results for Q4 and FY 2022, highlighting a net loss of $8.9 million for Q4 and $31.2 million for the full year, compared to losses of $4.3 million and $16.2 million in 2021.

The company successfully completed its IPO in November 2022 and initiated a Phase 2 trial for ACR-368 in patients with platinum-resistant cancers. Acrivon aims to advance precision oncology through its OncoSignature test and has made significant progress, including partnerships and team expansions. As of December 31, 2022, it had $169.6 million in cash, expected to fund operations through Q4 2024.

Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Peter Blume-Jensen will present an overview on March 13, 2023, at 3:20 p.m. ET during the Oppenheimer 33rd Annual Healthcare Conference. The presentation will be accessible via a live webcast on Acrivon's website. Acrivon focuses on developing precision oncology medicines using its proprietary AP3 platform, identifying patients whose tumors are sensitive to specific treatments. The company is advancing its lead candidate, ACR-368, a selective inhibitor targeting CHK1 and CHK2, in a Phase 2 trial across various tumor types. Acrivon’s OncoSignature companion diagnostics are in development to optimize patient treatment.

Acrivon Therapeutics announced that CEO Peter Blume-Jensen will join a panel on ovarian cancer at the Cowen 43rd Annual Health Care Conference on March 8, 2023, discussing ACR-368, a DNA Damage Response inhibitor in clinical testing for platinum-resistant advanced ovarian cancer.

The Phase 2 trial evaluates ACR-368 in patients with confirmed platinum-resistant ovarian cancer, who have had up to six prior therapies. Patients will be assigned to treatment arms based on results from the OncoSignature® predictive test. Acrivon aims to demonstrate the drug's anti-tumor activity and its potential in combination with gemcitabine.

Acrivon Therapeutics, Inc. (Nasdaq: ACRV) has announced the pricing of its initial public offering (IPO), offering 7,550,000 shares at $12.50 each, targeting gross proceeds of about $99.4 million. A concurrent private placement of 400,000 shares will occur with existing stockholder Chione Limited. The IPO is set to begin trading on Nasdaq on November 15, 2022, closing on November 17, 2022, pending customary conditions. Acrivon is focused on precision oncology treatments backed by its proprietary AP3 platform, and its lead candidate ACR-368 is in a Phase 2 trial.